1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

New appointment at Greenleaf Health

 
• By Sue Sutter

Former US FDA commissioner Dr Andrew von Eschenbach has joined the regulatory consulting firm Greenleaf Health as a senior advisor. Dr von Eschenbach, a urologic oncologist and former director of the National Cancer Institute, left the FDA on January 20th. At Greenleaf he will be reunited with Patrick Ronan, the firm's founder and president, who served as Dr von Eschenbach's chief of staff at the FDA in 2005 and 2006. Mr Ronan was vice-president of regulatory policy and external affairs at Novartis before starting his own consulting firm last year.

Former US FDA commissioner Dr Andrew von Eschenbach has joined the regulatory consulting firm Greenleaf Health as a senior advisor. Dr von Eschenbach, a urologic oncologist and former director of the National Cancer Institute, left the FDA on January 20th. At Greenleaf he will be reunited with Patrick Ronan, the firm's founder and president, who served as Dr von Eschenbach's chief of staff at the FDA in 2005 and 2006. Mr Ronan was vice-president of regulatory policy and external affairs at Novartis before starting his own consulting firm last year.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

 
• By Vibha Ravi

As AI-driven firms like Insilico, big pharma like J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s respectively advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?

Sino Biopharm Scoops LaNova In Chinese Pharma’s Biggest Biotech Buyout So Far

 
• By Dexter Jie Yan

Sino Biopharm will pay almost $1bn to acquire what target LaNova’s CEO described as an “exploding” pipeline, which includes six clinical-stage candidates in the oncology area.

Actuate Is Looking For A Buyer To Advance Pancreatic Cancer Candidate

 
• By Jessica Merrill

After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By Kevin Grogan

Swiss major confident that new oncology drugs will fill revenue gap.

More from Therapeutic Category

In Brief: Kezar Plots Lupus Revival For Zetomipzomib As FDA Lifts Hold On Hepatitis Trial

 
• By Manas Mishra

The go-ahead to resume a trial for its only drug candidate, zetomipzomib, in hepatitis could give Kezar a glimmer of hope of reviving another halted study in lupus nephritis.

Hopes Rise For Sickle Cell Gene Therapy Access As 33 States Join CMS Program

 
• By Alaric DeArment

CMS said that 33 US states plus the District of Columbia and Puerto Rico had joined a program whereby the agency negotiates outcomes-based contracts on their behalf.

AstraZeneca’s Amyloidosis Drug Fails In Phase III But Subgroup Hopes Persist

 
• By Andrew McConaghie

Anselamimab was expected to complement Alexion's portfolio of amyloid therapies, but regulators will have to be convinced of its benefits to a patient subgroup in the CARES trial.